Introduction: severe sepsis and drotrecogin alfa (...[Crit Care. 2007]

SearchDatabase nameforSearch term

Advanced Search

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 0

Click to change filter selection through MyNCBI.

1: Crit Care. 2007;11 Suppl 5:S1. Links

Introduction: severe sepsis and drotrecogin alfa (activated).

Artigas A, Martin CD.

Critical Care Center, Sabadell Hospital, CIBER Enfermedades Respiratorias, Parc Tauli University Institute, Parc Tauli, 08208 Sabadell, Spain. aartigas@tauli.cat.

PMID: 18269688 [PubMed - indexed for MEDLINE]

Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
Pediatrics. 2004 Jan; 113(1 Pt 1):7-17.

[Pediatrics. 2004]
ReviewDrotrecogin alfa (activated) in the treatment of severe sepsis.
Expert Rev Anti Infect Ther. 2006 Aug; 4(4):537-47.

[Expert Rev Anti Infect Ther. 2006]
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.
Crit Care Med. 2005 Oct; 33(10):2266-77.

[Crit Care Med. 2005]
ReviewClinical trials in severe sepsis with drotrecogin alfa (activated).
Crit Care. 2007; 11 Suppl 5:S5.

[Crit Care. 2007]
ReviewThe development of drotrecogin alfa (activated) for the treatment of severe sepsis.
Int J Artif Organs. 2004 May; 27(5):360-70.

[Int J Artif Organs. 2004]
» See reviews... | » See all...

Recent Activity

Clear Turn Off Turn On

Introduction: severe sepsis and drotrecogin alfa (activated).Introduction: severe sepsis and drotrecogin alfa (activated).

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Display Show

Introduction: severe sepsis and drotrecogin alfa (activated).

Related articles

Recent Activity